MIST

0.37117.06%
PT

Philip T. Sager

Chief Medical Advisor & Member of the Scientific Advisory Board

Dr. Philip T. Sager, M.D., FACC, FAHA, FHRS, serves as a Member of Scientific Advisory Board of CinCor Pharma, Inc. He was Senior Clinical Advisor and was Chief Medical Officer at Thryv Therapeutics Inc. (formerly known as LQT Therapeutics, Inc) since August 2021 until November 2024. He serves as Member of the Scientific Advisory Board at Milestone Pharmaceuticals Inc and has been its Chief Medical Advisor since 2020. Dr. Sager served as Chief Medical Advisor of Milestone Pharmaceuticals Inc. He served as the Chief Medical Officer of CardioDx, Inc. since 2008. He joined the pharmaceutical industry after 11 years at the UCLA School of Medicine where he served as its Faculty Member in cardiology. He served as Medical Director of the Schering-Plough Research Institute, where he played key roles in the development and NDA approval of drugs to treat hypercholesterolemia. Prior to joining CardioDx in 2008, he served as an Executive Director of AstraZeneca Inc., where he was responsible for the medical/scientific leadership of several worldwide pharmaceutical development programs and corporate strategies regarding QT/arrhythmia issues in drug development. He is a cardiologist and electrophysiologist who has held senior leadership positions within the pharmaceutical industry and academia and has played a significant role in the development of metabolic and cardiovascular drugs and cardiovascular safety issues in drug development. He had been a Director of Anthera Pharmaceuticals, Inc. since June 13, 2014. He has been a Member of Medical Advisory Board at BioTelemetry, Inc. since March 2009. He has been a Member of Scientific Advisory Board of NewCardio, Inc. since December 2008. He has been a Member of the Medical Advisory Board of CardioNet, Inc. since March 2009. He is Board certified in Internal Medicine, Cardiology and Cardiac Electrophysiology and has published more than 150 scientific manuscripts and abstracts. From 2001 to 2004, he served as a Director of Schering-Plough Research Institute, where he played key roles for Vytorin and Zetia. He serves as Member of the FDA-sponsored Cardiac Safety Research Consortium and is a Member of the International Committee on Harmonization (ICH) E14 Expert Group. He played major roles in the development of Crestor, Vytorin, Zetia, Ranexa, Letairis and Brilinta. Dr. Sager received B.S. degrees from the Massachusetts Institute of Technology with Biology and Chemistry and a M.D. from Yale University, where he also completed his Medical Internship, Residency, Cardiology Fellowship and Cardiac Electrophysiology Fellowships. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Physicians and the Heart Rhythm Society.

Positions